Pancreatic Cancer Tumor Vaccines: 2025 Trials
Summary of Pancreatic Cancer Vaccine Clinical Trials
HereS a summary of the three pancreatic cancer vaccine clinical trials described in the text:
1. Perioperative immunotherapy for Surgically Resectable Pancreatic Adenocarcinoma (May 2025 – Dec 2028)
* Phase: Pilot Study (likely Phase II based on description)
* Approach: Combines immunotherapy with surgery. Patients receive either:
* GVAX whole-cell vaccine + balstilimab (anti-PD-1) + AGEN2373 (anti-CD137)
* mKRASvax (mutant KRAS peptide vaccine) + balstilimab (anti-PD-1) + AGEN2373 (anti-CD137)
* Key Objectives:
* determine optimal AGEN2373 dose.
* Evaluate immune activation, recurrence-free survival, and overall survival.
* Compare GVAX vs. mKRASvax vaccine platforms.
* Focus: Improving long-term cure rates in early-stage pancreatic cancer through intensified anti-tumor immunity.
2. Mutant KRAS-Targeted Long Peptide Vaccine in High-Risk Individuals (April 2022 – May 2031)
* Phase: I
* Approach: Preventive vaccination with a mutant-KRAS long peptide vaccine (with poly-ICLC adjuvant) before cancer develops.
* Target Population: Individuals at high risk:
* Genetically/familiarly predisposed
* Patients with pancreatic cystic neoplasms
* Key Objectives:
* Assess safety and immune response.
* Measure KRAS-specific T-cell activation.
* evaluate long-term immune persistence.
* Focus: preventing KRAS-driven pancreatic cancer through early immunotherapy.
3. KRAS-Targeted Vaccine With Balstilimab and Botensilimab in MMR-p Colorectal and Pancreatic Cancer (Details incomplete in provided text)
* Phase: I
* Approach: KRAS-targeted vaccine combined with balstilimab and botensilimab.
* Target Population: Patients with MMR-p (mismatch repair proficient) colorectal and pancreatic cancer.
* Study ID: NCT06411691
Overall Trends:
* KRAS Targeting: A meaningful focus on vaccines targeting the KRAS mutation, a common driver of pancreatic cancer.
* Immunotherapy Combination: Trials frequently combine vaccines with checkpoint inhibitors (like balstilimab) to enhance immune response.
* Preventive vs. Therapeutic: Research is exploring both preventing cancer in high-risk individuals and treating existing cancer with immunotherapy.
* Johns Hopkins Involvement: The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University is a key location for these trials.